• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting PR1 in myeloid leukemia.

作者信息

Alatrash Gheath, Molldrem Jeffrey J, Qazilbash Muzaffar H

机构信息

Department of Stem Cell Transplantation and Cellular Therapy, Associate Professor of Medicine, Section of Transplant Immunology, Houston, TX, USA.

出版信息

Oncotarget. 2017 Dec 18;9(4):4280-4281. doi: 10.18632/oncotarget.23403. eCollection 2018 Jan 12.

DOI:10.18632/oncotarget.23403
PMID:29435102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5796973/
Abstract
摘要

相似文献

1
Targeting PR1 in myeloid leukemia.靶向髓系白血病中的PR1
Oncotarget. 2017 Dec 18;9(4):4280-4281. doi: 10.18632/oncotarget.23403. eCollection 2018 Jan 12.
2
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.一种对PR1/HLA - A2具有特异性的新型TCR样嵌合抗原受体（CAR），当在成人外周血和脐带血T细胞中表达时，可在体外有效靶向髓系白血病。
Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.
3
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.一种新型靶向白血病抗原 PR1/HLA-A2 的 T 细胞结合双特异性抗体。
Front Immunol. 2019 Jan 18;9:3153. doi: 10.3389/fimmu.2018.03153. eCollection 2018.
4
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.PR1肽疫苗在髓系恶性肿瘤中诱导特异性免疫并产生临床反应。
Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.
5
PR1 vaccination in myeloid malignancies.髓系恶性肿瘤中的PR1疫苗接种
Expert Rev Vaccines. 2008 Sep;7(7):867-75. doi: 10.1586/14760584.7.7.867.
6
PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.PR1特异性细胞毒性T淋巴细胞在脐带血中相对常见，并且可以有效地扩增以靶向髓系白血病。
Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007.
7
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.PR1-人白细胞抗原A2四聚体可用于从健康供体中分离出能选择性裂解慢性粒细胞白血病的低频细胞毒性T淋巴细胞。
Cancer Res. 1999 Jun 1;59(11):2675-81.
8
Neutrophil granule proteins as targets of leukemia-specific immune responses.中性粒细胞颗粒蛋白作为白血病特异性免疫反应的靶点。
Curr Opin Hematol. 2006 Jan;13(1):15-20. doi: 10.1097/01.moh.0000190112.92908.3e.
9
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.用免疫疗法靶向白血病抗原 PR1 治疗多发性骨髓瘤。
Clin Cancer Res. 2018 Jul 15;24(14):3386-3396. doi: 10.1158/1078-0432.CCR-17-2626. Epub 2018 Apr 16.
10
Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.8F4（一种T细胞受体样抗PR1/HLA - A2抗体）在体内对原发性人类急性髓系白血病的活性。
Leukemia. 2016 Jul;30(7):1475-84. doi: 10.1038/leu.2016.57. Epub 2016 Mar 8.

引用本文的文献

1
Breaking Boundaries: Immunotherapy for Myeloid Malignancies.突破界限：髓系恶性肿瘤的免疫疗法
Cancers (Basel). 2024 Aug 6;16(16):2780. doi: 10.3390/cancers16162780.
2
Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.用于癌症广泛适用的过继性细胞疗法的同种异体肿瘤抗原特异性T细胞
Cancer Treat Res. 2022;183:131-159. doi: 10.1007/978-3-030-96376-7_4.
3
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.基于 T 细胞的急性髓系白血病免疫疗法：当前概念和未来发展。

本文引用的文献

1
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.PR1肽疫苗在髓系恶性肿瘤中诱导特异性免疫并产生临床反应。
Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.
2
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.一种对PR1/HLA - A2具有特异性的新型TCR样嵌合抗原受体（CAR），当在成人外周血和脐带血T细胞中表达时，可在体外有效靶向髓系白血病。
Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.
3
Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.
Leukemia. 2021 Jul;35(7):1843-1863. doi: 10.1038/s41375-021-01253-x. Epub 2021 May 5.
4
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.基于 T 细胞受体的免疫疗法的经验设计与理性设计。
Front Immunol. 2021 Jan 25;11:585385. doi: 10.3389/fimmu.2020.585385. eCollection 2020.
5
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.近期治疗进展以及纳米技术、组合产品和免疫疗法在改变急性髓细胞白血病治疗格局中的作用。
Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z.
6
ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives.抗中性粒细胞胞浆抗体相关性血管炎与血液系统恶性肿瘤：从过去到未来的经验教训。
J Immunol Res. 2019 May 6;2019:1732175. doi: 10.1155/2019/1732175. eCollection 2019.
7
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.采用表达天然 TCR 的抗原特异性 T 细胞的过继免疫疗法。
Cancer Immunol Res. 2019 Apr;7(4):528-533. doi: 10.1158/2326-6066.CIR-18-0888.
8
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.一种新型靶向白血病抗原 PR1/HLA-A2 的 T 细胞结合双特异性抗体。
Front Immunol. 2019 Jan 18;9:3153. doi: 10.3389/fimmu.2018.03153. eCollection 2018.
8F4（一种T细胞受体样抗PR1/HLA - A2抗体）在体内对原发性人类急性髓系白血病的活性。
Leukemia. 2016 Jul;30(7):1475-84. doi: 10.1038/leu.2016.57. Epub 2016 Mar 8.
4
Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.同种反应性细胞毒性 T 细胞为解析免疫肽组和揭示大量肿瘤相关自身表位提供了手段。
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):403-8. doi: 10.1073/pnas.1306549111. Epub 2013 Dec 16.
5
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.一种新型的组织蛋白酶 G 衍生的 HLA-A*0201 限制性肽是急性髓系白血病的有效免疫治疗靶点。
Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.
6
An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.一种抗 PR1/HLA-A2 T 细胞受体样抗体介导针对急性髓系白血病祖细胞的补体依赖性细胞毒性。
Blood. 2011 Apr 21;117(16):4262-72. doi: 10.1182/blood-2010-07-299248. Epub 2011 Feb 4.
7
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.髓系恶性肿瘤患者接受PR1和WT1肽联合疫苗接种后的白血病相关抗原特异性T细胞反应。
Blood. 2008 Jan 1;111(1):236-42. doi: 10.1182/blood-2007-08-108241. Epub 2007 Sep 17.
8
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.特定T淋巴细胞可能参与慢性粒细胞白血病清除的证据。
Nat Med. 2000 Sep;6(9):1018-23. doi: 10.1038/79526.